FIELD: pharmaceutics.
SUBSTANCE: present group of inventions relates to pharmaceutics, in particular to pharmaceutical compositions based on semaglutide for the treatment or prevention of diabetes and obesity, and kits containing these compositions. Liquid pharmaceutical compositions, according to the invention, contain 0.1-10 mg/ml of semaglutide, which is GLP-1-based peptide, and no more than 0.01% (weight/weight) of phenol.
EFFECT: implementation of the invention allows for obtaining liquid pharmaceutical compositions based on semaglutide, which have improved chemical and/or physical stability.
17 cl, 8 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE COMPOSITIONS BASED ON SEMAGLUTIDE AND THEIR USE | 2019 |
|
RU2803237C2 |
| SEMAGLUTIDE IN DRUG THERAPY | 2018 |
|
RU2800651C2 |
| STABILIZED PHARMACEUTICAL COMPOSITIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | 2014 |
|
RU2702345C2 |
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN | 2017 |
|
RU2758367C2 |
| SEMAGLUTIDE IN CARDIOVASCULAR CONDITIONS | 2017 |
|
RU2768283C2 |
| GLP-1 PEPTIDE SPRAY DRYING METHOD | 2020 |
|
RU2815061C2 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
| ACYLATED DERIVATIVE OF GLP-1 | 2019 |
|
RU2773242C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT | 2019 |
|
RU2804318C2 |
